Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 10/20 | 0.76 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.67 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.67 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | GSK3A | P49840 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12090581 | 0.88 | ACP1 (0.67) | ACP1TGFBR1ABCG2ABCB1ABCC1 | |
| SCHEMBL12090769 | 0.87 | ACP1 (1.00) | ACP1ABCG2ABCB1 | |
| SCHEMBL12090610 | 0.86 | ACP1 (0.60) | ACP1TGFBR1ABCG2ABCB1ABCC1 | |
| SCHEMBL12090651 | 0.85 | ACP1 (0.65) | ACP1TGFBR1ABCG2ABCB1 | |
| SCHEMBL12090557 | 0.85 | ACP1 (0.69) | ACP1TGFBR1ABCG2ABCB1ABCC1 | |
| SCHEMBL12090551 | 0.85 | ABCG2 (0.70) | ACP1TGFBR1ABCG2ABCB1ABCC1 | |
| SCHEMBL12090368 | 0.85 | ACP1 (0.79) | ACP1TGFBR1ABCG2ABCB1KDM4E | |
| SCHEMBL12090376 | 0.84 | ACP1 (0.64) | ACP1TGFBR1ABCG2ABCB1ABCC1 | |
| SCHEMBL12090552 | 0.84 | TGFBR1 (0.70) | ACP1TGFBR1ABCG2ABCB1KDM4E | |
| SCHEMBL22201279 | 0.83 | ABCG2 (0.85) | ACP1TGFBR1ABCG2ABCB1ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987301-B2 | Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors | MERCK PATENT GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987301-B2 | Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors | MERCK PATENT GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20120225875-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-06 | — | — | US | disclosed |
| US-20120225875-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-06 | — | — | US | disclosed |
| WO-2011054433-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225875-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | TGFBR1, TGFBR2, TGFB1 | ACP1 4047/4885TGFBR1 1/4885ABCG2 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.